Neurocrine Biosciences | Der Umsatz





Der Umsatz Veränderung Datum
AbbVie USD 16.62B 840M 2025-12
Acadia Pharmaceuticals USD 284M 5.4M 2025-12
Agios Pharmaceuticals USD 19.97M 7.07M 2025-12
ALKERMES USD 384.5M 9.7M 2025-12
Alnylam Pharmaceuticals USD 1.1B 150M 2025-12
Amgen USD 9.9B 340M 2025-12
Biogen USD 2.28B 250M 2025-12
BioMarin Pharmaceutical USD 875M 99M 2025-12
Cytokinetics USD 17.76M 15.83M 2025-12
Enanta Pharmaceuticals USD 16.96M 50.68M 2024-12
Exelixis USD 598.66M 860K 2025-12
Gilead Sciences USD 7.93B 130M 2025-12
Halozyme Therapeutics USD 451.76M 97.76M 2025-12
Incyte USD 1.51B 140M 2025-12
Ionis Pharmaceuticals USD 203M 46M 2025-12
Nektar Therapeutics USD 24.12M 635K 2024-09
Neurocrine Biosciences USD 805.5M 10.6M 2025-12
Pfizer USD 17.58B 880M 2025-12
Prothena USD 2.42M 2M 2025-09
Regeneron Pharmaceuticals USD 3.88B 130M 2025-12
Repligen USD 197.91M 8.91M 2025-12
Rigel Pharmaceuticals USD 55.31M 18.47M 2024-09
Sarepta Therapeutics USD 442.9M 43.5M 2025-12
Teva Pharmaceutical Industries USD 14.63B 10M 2025-12
Ultragenyx Pharmaceutical USD 207M 47M 2025-12
Vertex Pharmaceuticals USD 3.19B 110M 2025-12
Xoma USD 25K 5M 2024-09


Neurocrine Biosciences Der Umsatz - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Mar 2026.